What's Happening?
SK bioscience has entered into a funding agreement with the Research Investment for Global Health Technology Foundation (RIGHT Foundation) to support the early clinical development of its RSV preventive monoclonal antibody candidate, RSM01. The company
received KRW 4 billion (approximately USD 3.0 million) to accelerate the Phase 1b clinical trial of RSM01 in infants. This candidate, licensed from the Gates Medical Research Institute, aims to provide continuous protection against RSV throughout the season with a single administration. SK bioscience plans to oversee the subsequent stages from the Phase 1b clinical trial through to commercialization. The company has secured exclusive global supply rights, with a dual commercialization strategy targeting both high-income and lower-income markets.
Why It's Important?
The development of RSM01 is significant as RSV is a major cause of severe respiratory infections in infants and young children, leading to substantial hospitalizations and healthcare burdens worldwide. The global RSV preventive antibody market is projected to reach USD 4.5 billion by 2032, indicating a growing demand for effective preventive solutions. SK bioscience's efforts to develop a globally competitive product could address unmet medical needs, particularly in lower-income countries, while also maximizing commercial value in advanced markets. This initiative reflects a broader commitment to enhancing global public health through innovative vaccine development.
What's Next?
SK bioscience will proceed with the Phase 1b clinical trial of RSM01, focusing on infants. The company plans to leverage its R&D and manufacturing capabilities to develop a product that meets global standards. The dual commercialization strategy will involve supplying affordable doses to lower-income countries while targeting high-income markets. The success of this project could pave the way for further advancements in SK bioscience's infectious disease pipeline, which includes next-generation vaccines for various diseases.
